Grace Therapeutics, Inc. (GRCE)
- Sector
- Healthcare
- Industry
- Biotechnology
- Last price
- $1.99
- As of
Kresmion compiles this page from GRCE's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.
Grace Therapeutics, Inc. (GRCE): 2 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-09-18.
See the full GRCE dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for GRCE on one page. Preview it with sample data, then open it live with a free account.
Preview the GRCE dossierActive signals for GRCE
- highCONSENSUS_BUY
3 tracked funds increased GRCE this 2026Q2, institutional consensus
- highINSTITUTIONAL_SURGE
CITADEL ADVISORS LLC added +727% to GRCE (2026Q2)
- mediumNEW_POSITION
TWO SIGMA INVESTMENTS, LP new position in GRCE
- highINSTITUTIONAL_SURGE
RENAISSANCE TECHNOLOGIES LLC added +88% to GRCE (2026Q1)
- mediumEARNINGS_BEAT
Q4-2026: Beat consensus by 74.4% - EPS $-0.06 vs $-0.2346 estimate
FREE, NO ACCOUNT
Every signal on GRCE, as it fires
You are seeing 5 of 9 signals recorded on GRCE since 2026-05-30.
The five above landed across 4 days. The other 4 were recorded on 1 other days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in GRCE (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| CITADEL ADVISORS LLCCUSIP 00439U104 · 2026Q2 | $794K | 0.00% | , |
| TWO SIGMA INVESTMENTS, LPCUSIP 00439U104 · 2026Q2 | $220K | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, GRCE
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
GRCE against its peers
GRCE's return on equity of -12.2% ranks in the 98th percentile of 20 Biotechnology sub-industry peers, fiscal periods ending between 2025-09-30 and 2026-06-30.
| Metric | GRCE | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | n/a | 110000 | n/a | 10 |
| Operating margin | n/a | -9718.8% | n/a | 8 |
| Net margin | n/a | -10212.0% | n/a | 8 |
| Return on equity | -12.2% | -123.1% | 98 | 20 |
| 1 year | -33.4% | -63.7% | 84 | 21 |
Peers (22): TVGN, CVM, VERU, LITS, FLNA, HOWL, IBO, IMA, ELTX, CRVO, TIL, MGX, CRBU, DWTX, GNTA, EDSA, ATNM, ANVS, SER, NNVC, INMB, EXOZ. Left out: BSEM (no annual filing), RLFTY (no annual filing), BCTX (period gap). Fiscal periods ending between 2025-09-30 and 2026-06-30. Every figure is one full fiscal year read from one annual filing (GRCE: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
Follow GRCE on a live board
Kresmion is a cross-asset market-intelligence terminal. Open a board scoped to GRCE for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.